COVID-19 clinical trials lack diversity

Article

COVID-19 clinical trials lack diversity

Trials need more Black, Indigenous and people of color to generalize results to larger U.S. population

Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials, according to a new perspective authored by faculty from the University of Georgia and University of Colorado and pharmacists from Phoebe Putney Memorial Hospital in Albany.

Published by the New England Journal of Medicine, the article calls on government agencies, medical journals, funders of research, among others, to diversify study participants in order to be able to generalize results to the larger U.S. population. Lead author is Daniel Chastain, a clinical assistant professor of pharmacy at UGA’s Albany campus. Co-authors also include Sharmon Osae and Henry Young from the UGA College of Pharmacy and Joeanna Chastain from Phoebe.

Story continues ... >>

The views and opinions expressed in the article are solely those of their authors, and do not necessarily reflect the opinions and beliefs of DiversityWork.com.